-====Heron Therapeutics announced (HRTX) : Breakthrough Therapy designation for pain drug

Heron Therapeutics announced that HTX-011 for postoperative pain management has received Breakthrough Therapy designation from the FDA 
Co states, "HTX-011 is the only long-acting local anesthetic to demonstrate significantly reduced postoperative pain and opioid use through 72 hours compared to bupivacaine solution, the standard-of-care local anesthetic for postoperative pain management, in Phase 3 studies. We look forward to working towards the submission of an NDA to the FDA for HTX-011 in the second half of 2018."

Long trade : HRTX +6% (8/17)

• 8/21:   #98  vol. 360 K

  

Long trade : HRTX +20% (7/17)